{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:28:18Z","timestamp":1791516498173,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neoadjuvant chemotherapy (NAC) with radical cystectomy (RC) is the preferred first-line treatment for localized muscle-invasive bladder cancer (MIBC). In recent years, octogenarians have been undergoing RC uneventfully, but studies showed older adults receive NAC less often. We studied the utilization and effect of RC with or without NAC in octogenarians and compared survival outcomes between responders and non-responders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In our retrospective study using the National Cancer Database (NCDB), we identified octogenarians with MIBC and urothelial histology who underwent RC with or without NAC between 2004 and 2018. The NAC cohort included patients who underwent RC with NAC, and the non-NAC cohort included those with or without adjuvant chemotherapy. The NAC cohort was subcategorized into responders and non-responders based on surgical pathology. Patients with comorbidity index\u2009&gt;\u20091 were not included, thereby excluding patients with possible renal impairment. After propensity-matching, we compared the overall survival (OS) between NAC and non-NAC cohorts and responders and non-responders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>33924 patients underwent RC, and 3056 octogenarians met our selection. Among them, 396 received NAC, and 2660 did not receive NAC. Among those who received NAC, 112(28.3%) experienced downstaging, and 223(56.4%) exhibited upstaging or no change (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). After propensity-matching, the median OS of the NAC and non-NAC cohorts were 51.6 months and 31.3 months, respectively (p&lt;0.001). Similarly, the median OS of responders and non-responders were 89.4 months and 26.5 months, respectively(<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In our study, we observed that NAC with RC for MIBC may help to improve OS among healthy octogenarians. Similarly, responders had better OS than non-responders.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-024-01548-y","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T10:04:16Z","timestamp":1721815456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pathological response and survival outcomes after neoadjuvant chemotherapy with radical cystectomy in octogenarians for muscle-invasive bladder cancer: an observational database study"],"prefix":"10.1186","volume":"24","author":[{"given":"Arjun Pon","family":"Avudaiappan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushan","family":"Prabhakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayer Simcha","family":"Sandman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muni","family":"Rubens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Garje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Eldefrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murugesan","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"1","key":"1548_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1548_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12967-020-02308-w","volume":"18","author":"W Fang","year":"2020","unstructured":"Fang W, Yang ZY, Chen TY, Shen XF, Zhang C. Ethnicity and survival in bladder cancer: a population-based study based on the SEER database. J Transl Med. 2020;18(1):145.","journal-title":"J Transl Med"},{"issue":"1","key":"1548_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.euo.2018.03.001","volume":"1","author":"N Hanna","year":"2018","unstructured":"Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, et al. Effectiveness of Neoadjuvant Chemotherapy for muscle-invasive bladder Cancer in the current Real World setting in the USA. Eur Urol Oncol. 2018;1(1):83\u201390.","journal-title":"Eur Urol Oncol"},{"key":"1548_CR4","doi-asserted-by":"crossref","unstructured":"Xu J, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2021. NCHS Data Brief. 2022(456):1\u20138.","DOI":"10.15620\/cdc:122516"},{"issue":"9","key":"1548_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u201366.","journal-title":"N Engl J Med"},{"issue":"1","key":"1548_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder Cancer: Summary of the 2020 guidelines. Eur Urol. 2021;79(1):82\u2013104.","journal-title":"Eur Urol"},{"issue":"1","key":"1548_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12894-020-00733-z","volume":"20","author":"A Hamid","year":"2020","unstructured":"Hamid A, Ridwan FR, Parikesit D, Widia F, Mochtar CA, Umbas R. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. BMC Urol. 2020;20(1):158.","journal-title":"BMC Urol"},{"issue":"6","key":"1548_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant chemotherapy for muscle-invasive bladder Cancer: a systematic review and two-step Meta-analysis. Oncologist. 2016;21(6):708\u201315.","journal-title":"Oncologist"},{"issue":"16","key":"1548_CR9","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"G Griffiths","year":"2011","unstructured":"Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1548_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","volume":"36","author":"O Fahmy","year":"2018","unstructured":"Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, K\u00fcbler H, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018;36(2):43\u201353.","journal-title":"Urol Oncol"},{"issue":"1","key":"1548_CR11","first-page":"21","volume":"36","author":"N Posielski","year":"2022","unstructured":"Posielski N, Koenig H, Ho O, Porter C, Flores JP. Use of Neoadjuvant Chemotherapy in Elderly patients with muscle-invasive bladder Cancer: a Population-based study, 2006\u20132017. Oncol (Williston Park). 2022;36(1):21\u201333.","journal-title":"Oncol (Williston Park)"},{"issue":"3","key":"1548_CR12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683\u201390.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"1548_CR13","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K, Loomis A, Gay G, Palis B, et al. Using the National Cancer Database for Outcomes Research: a review. JAMA Oncol. 2017;3(12):1722\u20138.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1548_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4111\/icu.20200132","volume":"61","author":"C McFerrin","year":"2020","unstructured":"McFerrin C, Davaro F, May A, Raza S, Siddiqui S, Hamilton Z. Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer. Investig Clin Urol. 2020;61(6):565\u201372.","journal-title":"Investig Clin Urol"},{"key":"1548_CR15","doi-asserted-by":"crossref","unstructured":"Macleod LC, Yabes JG, Yu M, Fam MM, Hale NE, Turner RM 2, et al. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2019;37(7):462\u20139.","DOI":"10.1016\/j.urolonc.2019.04.006"},{"key":"1548_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.canep.2018.11.007","volume":"58","author":"E Mazzone","year":"2019","unstructured":"Mazzone E, Knipper S, Mistretta FA, Tian Z, Preisser F, Gallina A, et al. Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis? Cancer Epidemiol. 2019;58:83\u20138.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"1548_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jjco\/hyz137","volume":"50","author":"M Nitta","year":"2020","unstructured":"Nitta M, Kuroda S, Nagao K, Higure T, Zakoji H, Miyakita H, et al. Effect of neoadjuvant chemotherapy in patients undergoing radical cystectomy for muscle-invasive bladder cancer: a retrospective, multi-institutional study. Jpn J Clin Oncol. 2020;50(1):73\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"1548_CR18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/iju.14533","volume":"28","author":"M Kubota","year":"2021","unstructured":"Kubota M, Kanno T, Inoue T, Yamasaki T, Okumura K, Ito K, et al. Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: a matched-pair analysis in a multicenter cohort. Int J Urol. 2021;28(6):656\u201364.","journal-title":"Int J Urol"},{"issue":"1","key":"1548_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1186\/s12885-022-10394-w","volume":"22","author":"CT M\u00f8ller","year":"2022","unstructured":"M\u00f8ller CT, St\u00f8er NC, Blindheim A, Berge V, Tafjord G, Foss\u00e5 SD, et al. Downstaging and survival after neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study. BMC Cancer. 2022;22(1):1301.","journal-title":"BMC Cancer"},{"issue":"12","key":"1548_CR20","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1007\/s11255-022-03339-6","volume":"54","author":"N van Ginkel","year":"2022","unstructured":"van Ginkel N, Hermans TJN, Meijer D, Boormans JL, Voortman J, Mertens L, et al. Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study. Int Urol Nephrol. 2022;54(12):3145\u201352.","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"1548_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/21681805.2019.1624611","volume":"53","author":"B Russell","year":"2019","unstructured":"Russell B, Sherif A, H\u00e4ggstr\u00f6m C, Josephs D, Kumar P, Malmstr\u00f6m PU, et al. Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. Scand J Urol. 2019;53(4):206\u201312.","journal-title":"Scand J Urol"},{"issue":"1","key":"1548_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/bju.15289","volume":"128","author":"F Soria","year":"2021","unstructured":"Soria F, Black PC, Fairey AS, Cookson MS, Yu EY, Kassouf W, et al. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. BJU Int. 2021;128(1):79\u201387.","journal-title":"BJU Int"},{"issue":"12","key":"1548_CR23","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1007\/s00345-021-03776-5","volume":"39","author":"F Claps","year":"2021","unstructured":"Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Boormans JL, Eckstein M, et al. Risk factors associated with positive surgical margins\u2019 location at radical cystectomy and their impact on bladder cancer survival. World J Urol. 2021;39(12):4363\u201371.","journal-title":"World J Urol"},{"key":"1548_CR24","doi-asserted-by":"crossref","unstructured":"Marcq G, Afferi L, Neuzillet Y, Nykopp T, Voskuilen CS, Furrer MA et al. Oncological outcomes for patients harboring positive Surgical margins following radical cystectomy for muscle-invasive bladder Cancer: a Retrospective Multicentric Study on Behalf of the YAU Urothelial Group. Cancers (Basel). 2022;14(23).","DOI":"10.3390\/cancers14235740"},{"issue":"4","key":"1548_CR25","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/j.clgc.2017.01.014","volume":"15","author":"AR Leone","year":"2017","unstructured":"Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, et al. Neoadjuvant Chemotherapy in Elderly patients with bladder Cancer: oncologic outcomes from a single Institution experience. Clin Genitourin Cancer. 2017;15(4):e583\u20139.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"1548_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/ecc.12282","volume":"24","author":"C Chau","year":"2015","unstructured":"Chau C, Wheater M, Geldart T, Crabb SJ. Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients. Eur J Cancer Care (Engl). 2015;24(2):155\u201362.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"4","key":"1548_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.eururo.2022.07.023","volume":"83","author":"A Gil-Jimenez","year":"2023","unstructured":"Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis DJ, Braaf L, et al. Assessment of Predictive genomic biomarkers for response to cisplatin-based Neoadjuvant Chemotherapy in bladder Cancer. Eur Urol. 2023;83(4):313\u20137.","journal-title":"Eur Urol"},{"issue":"4","key":"1548_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucian\u00f2 R, et al. Updated results of PURE-01 with preliminary activity of Neoadjuvant Pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77(4):439\u201346.","journal-title":"Eur Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01548-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01548-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01548-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T10:05:55Z","timestamp":1721815555000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01548-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1548"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01548-y","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent and Ethics review are not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}